1

Geron

#6355

Rank

$745.19M

Marketcap

US United States

Country

Geron
Leadership team

Ms. Olivia Kyusuk Bloom (Exec. VP of Fin., CFO & Treasurer)

Dr. John A. Scarlett M.D. (Chairman, Pres & CEO)

Dr. Andrew J. Grethlein (Exec. VP & COO)

Products/ Services
Biopharma, Biotechnology, Health Diagnostics, Pharmaceutical
Number of Employees
50 - 100
Headquarters
Menlo Park, California, United States
Established
1990
Company Registration
SEC CIK number: 0000886744
Revenue
500K - 2M
Traded as
GERN
Social Media
Overview
Location
Summary
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
History

Geron Corporation was founded in 1990. In the early years, the company focused on the development of small-molecule pharmaceuticals, and in 2009, Geron transitioned to a full-time focus on the development of therapeutics for oncology and stem cell-based regenerative medicine applications.

Mission
Geron Corporation's mission is to develop therapeutics that have the potential to meaningfully improve and extend the lives of individuals with life-threatening and debilitating diseases.
Vision
Geron Corporation's vision is to become a leader in the discovery and development of life-saving and life-changing drugs that address unmet medical needs.
Key Team

Ms. Melissa A. Kelly Behrs (Exec. VP of Bus. Operations & Chief Alliance Officer)

Ms. Aron Feingold (VP of Investor Relations & Corp. Communications)

Mr. Stephen N. Rosenfield J.D. (Exec. VP, Chief Legal Officer & Corp. Sec.)

Mr. Anil Kapur (Exec. VP of Corp. Strategy & Chief Commercial Officer)

Ms. Shannon Odam (VP of HR)

Mr. Edward E. Koval (Exec. VP & Chief Bus. Officer)

Dr. Faye Feller M.D. (Exec. VP & Chief Medical Officer)

Recognition and Awards
Geron Corporation was recognized as an Outstanding Performer by the consulting firm Avalere Health in 2020 and is a multiple recipient of the R&D 100 Award for excellence in research and development. The company has also received international and national awards for its therapeutic programs targeting cancer and other diseases.
References

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Geron
Leadership team

Ms. Olivia Kyusuk Bloom (Exec. VP of Fin., CFO & Treasurer)

Dr. John A. Scarlett M.D. (Chairman, Pres & CEO)

Dr. Andrew J. Grethlein (Exec. VP & COO)

Products/ Services
Biopharma, Biotechnology, Health Diagnostics, Pharmaceutical
Number of Employees
50 - 100
Headquarters
Menlo Park, California, United States
Established
1990
Company Registration
SEC CIK number: 0000886744
Revenue
500K - 2M
Traded as
GERN
Social Media